MedPath

Safety and Efficacy of Low Temperature Contrast in UAP Patients During PCI (LOTA-I)

Not Applicable
Completed
Conditions
Unstable Angina Pectoris
Interventions
Other: low temperature contrast
Registration Number
NCT03700567
Lead Sponsor
Nanjing First Hospital, Nanjing Medical University
Brief Summary

Percutaneous coronary intervention (PCI) has become one of the main treatments for rapid recovery of revascularization in patients with coronary heart disease (CHD). PCI has some advantages, such as easy operation, small trauma and rapid recovery. It can significantly improve myocardial ischemic symptom and reduce the incidence of cardiovascular adverse events in CHD patients. However, many studies have found that the incidence of PCI-related myocardial injury is relatively high, and affect the efficacy of PCI and prognosis in patients with unstable angina pectoris (UAP). A meta-analysis of a total of 7578 patients with UAP from 15 studies who underwent PCI was found to have a 28.7% increase in myocardial biomarkers after PCI. The objective of this randomized control trial is to gain a clinical insight on the use of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients. The primary objective is assess efficacy and safety of low temperature contrast for the treatment of PCI-related myocardial injury in UAP patients.

Detailed Description

The current study is designed as a multicenter, randomized and prospective study aiming to compare the change in levels of myocardial injury biomarkers (such as TNI and CK-MB) between low temperature contrast group and room temperature contrast group. Based on previous study, the incidence rate of PCI-related myocardial injury is 28.7% in UAP patients undergoing PCI. And in our study the expected incidence rate of PCI-related myocardial injury is up to 14.3% in UAP patients undergoing PCI after treatment with low temperature contrast. Moreover, the investigators estimated 10% loss follow-up of these patients in each arm. As a result, a total of 440 UAP patients were required, and with 220 patients per group as a ratio of 1:1 randomization.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
440
Inclusion Criteria
  • De novo lesions
  • Those who meet the diagnostic criteria of unstable angina pectoris
  • New generation drug eluting stent implantation
  • Only single coronary artery treated at this time
Exclusion Criteria
  • Those who meet the diagnostic criteria of acute myocardial infarction
  • Those who meet the diagnostic criteria of stable angina pectoris
  • Patients with cardio-genic shock
  • Patients with multiple organ failure
  • Patients allergic to contrast
  • Patients who can not tolerate dual antiplatelet therapy
  • Patients who can't tolerate anticoagulation
  • Recently infected patients
  • Patients with hepatorenal dysfunction
  • Thrombotic lesion of coronary artery
  • Chronic total coronary occlusion lesion
  • Patients with complex coronary bifurcation requiring two stent strategy
  • Severe coronary calcified lesion
  • Patients with percutaneous coronary angioplasty
  • Patients with directional coronary atherectomy or rotational atherectomy
  • Patients with drug coated balloon treatment
  • Patients with bioabsorbable vascular scaffold implantation
  • Previous percutaneous coronary intervention or coronary artery bypass graft
  • Patients with active stage of autoimmune disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
low temperature contrastlow temperature contrastA total of 220 patients are assigned to low temperature contrast group after randomization schedule.
Primary Outcome Measures
NameTimeMethod
The incidence rate of PCI-related myocardial injury in UAP patients 3 days after PCI3 days after PCI

the incidence rate of PCI-related myocardial injury indicated by the changes of myocardial injury biomarkers (such as TNI and CK-MB) in UAP patients between low temperature contrast and room temperature contrast groups

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (7)

The People's hospital of Yixing

🇨🇳

Yixing, Jiangsu, China

The First People's Hospital of Changzhou

🇨🇳

Changzhou, Jiangsu, China

The First People's Hospital of Lianyungang

🇨🇳

Lianyungang, Jiangsu, China

The First People's Hospital of Chuzhou

🇨🇳

Chuzhou, Anhui, China

MingGuang People's Hospital

🇨🇳

Chuzhou, Anhui, China

The Affiliated Hospital of Xuzhou Medical University

🇨🇳

Xuzhou, Jiangsu, China

Nanjing First Hospital

🇨🇳

Nanjing, Jiangsu, China

© Copyright 2025. All Rights Reserved by MedPath